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INTRODUCTION
Despite the recent improvements in per-
forming radical retropubic prostatectomy that
have led to a considerable decrease in its com-
plication rate, erectile dysfunction still repre-
sents a major problem.1 Even with properly
trained professionals, erectile dysfunction rates
range dramatically according to the evaluation
of the patients. Although the complete loss of
erection had become less frequent after the
emergence of the nerve-sparing technique,2
some authors have reported up to 75% mild
to moderate erectile dysfunction due to this
surgery.3
In addition to the marked advance in sur-
gical technique, the treatment of erectile dys-
function has also changed profoundly over the
last two years, due to the advent of oral drugs,
especially sildenafil.4
Unfortunately, experiences using this
modern and less invasive method in the
treatment of impotence caused by radical
prostatectomy have been disappointing,5 as
have been the poor results obtained using
MUSE (transurethral alprostadil) for the
same purpose.6
Considering our previously published7, 8
excellent results from using self-injection
therapy in the treatment of impotence in pa-
tients with unknown etiology, our aim was to
evaluate the response to self-injection therapy
in those patients submitted to radical prosta-
tectomy due to localized prostate cancer.
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METHODS
A retrospective clinical study was con-
ducted on 168 men who were impotent be-
cause of radical retropubic prostatectomy. This
surgery had been performed by many differ-
ent surgeons in order to treat localized pros-
tate cancer, during a period of 96 months
(from May 1, 1991 to May 31, 1999), in a
university referral center. To be included in
the study, the patients needed to have had
normal erectile function prior to surgery, as
well as being in a stable relationship. The age
of these patients ranged from 43 to 78 years
(median of 61 years).
The period between the surgery and the
onset of treatment ranged from 4 to 84
months (median of 26 months). The pa-
tients had undergone the nerve-sparing
technique, with the objective of preserving
erectile function.2 In 92 patients, at least one
neurovascular bundle was preserved and in
61 patients the preservation was bilateral.
For 15 patients there was no data available
regarding this matter.
Of these 168 patients, 42 had prior treat-
ment using oral sildenafil, 17 received oral
yohimbine, 11 used the vacuum device and
another 8 patients used transurethral
alprostadil therapy (MUSE). None of the pa-
tients managed with medicinal treatment had
successful outcomes, while among the patients
treated with the vacuum device there was dis-
satisfaction with the method.
The only new procedure that the 168 pa-
tients underwent was the intracavernous in-
jection of 0.2 ml of a solution of papaverine
(22.6 mg), phentolamine (1.34 mg) and pros-
taglandin E1 (13.4 mg) in the consultation
office, as described previously.9
After this, the patients were trained to per-
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CONTEXT: Despite the recent improvements in perform-
ing radical retropubic prostatectomy that have led
to a considerable decrease in the complication rate,
erectile dysfunction still represents a major prob-
lem. Moreover, less invasive treatment options that
are emerging for erectile dysfunction have not shown
satisfactory results in managing these patients.
OBJECTIVE: To study the efficacy and side effects of
self-injection therapy in the treatment of men who
had become impotent after undergoing radical
prostatectomy due to prostate cancer, over a study
period of 96 months.
DESIGN: Observational study.
SETTING: University Referral Center.
PARTICIPANTS: 168 patients with erectile dysfunc-
tion, aged 43 to 78 years old, who underwent
radical retropubic prostatectomy due to localized
prostate cancer.
PROCEDURES: The patients were treated with self-in-
jection therapy using papaverine, phentolamine
and prostaglandin E1, at home.
RESULTS: This study showed an acceptable 94.6% suc-
cess rate, with no life-threatening complications.
In addition to this, our series presented a 13.1%
cure rate with this therapy.
CONCLUSION: Self-injection therapy with papaver-
ine, phentolamine and prostaglandin E1 is effec-
tive and safe in the treatment of erectile dysfunc-
tion after radical prostatectomy.
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form the self-injection at home and to return
every 30 days to the office. An emergency tel-
ephone number was given to the patients to
be used in case of side effects or priapism.
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RESULTS
All the 168 patients presented full erec-
tions during the office test. The duration of
these erections ranged from 20 to 210 min-
utes (median of 30 minutes). Based upon these
results, the initial dose to be used at home was
chosen. The mean dose for each patient ranged
from 0.2 ml to 0.4 ml, with a minimum dose
of 0.1 ml and maximum dose of 0.8 ml.
At home, the success rate (sexual inter-
course with a hard erection) was 94.6%. All
patients reported mild pain or discomfort
and about 15% developed penile ecchymo-
sis during the first three or four self-injec-
tions at home, which is believed to have
been due to the patients’ learning period.
Only 19 patients (11.3%) reported pro-
longed erection, lasting from 3 to 10 hours.
Among these 19 patients only 3 reported
erections lasting over 6 hours, although not
full. In these cases, conservative manage-
ment was conducted. All episodes of pro-
longed erections were resolved spontane-
ously, at the patients’ homes. The prolonged
erection episodes were all reported in the
first three months of self-injection therapy.
During the treatment, 22 patients
(13.1%) recovered full erections without any
therapy. The ages of these 22 patients ranged
from 43 to 57 years (median 55 years) after 5
to 18 months (median of 14 months) of treat-
ment and 7 to 22 months (median of 9
months) after radical prostatectomy.
The follow-up ranged from 5 to 72 months
(median 29 months). Except among patients
for whom therapy was unsuccessful, the self-
injection therapy was performed by all patients
during the whole follow-up period, with at least
one injection each week. Nevertheless, there was
wide variation in injection frequency during
the study, although the patients were warned
to avoid injections on two consecutive days.
Neither penile fibrosis nor nodes were observed
during the follow-up.
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DISCUSSION
Sexual dysfunction is a well-recognized
complication of abdominal and pelvic surgery.
As most of these procedures are performed on
elderly patients, there has in the past been a
tendency to disregard the importance of loss
of potency. However, some men now have
expectations of unimpaired sexual function
well into their seventh or even eighth decades.
Impotence can, therefore, have a profound
effect on their quality of life.
On the other hand, as prostatic carci-
noma continues to undergo a real increase
in incidence1 and diagnosis tends to be made
at earlier stages than in the past,10 an increas-
ing number of men are being offered treat-
ment by radical prostatectomy, usually via
the retropubic route. Traditionally, impo-
tence was inevitable after this procedure.
However, in the early 1980’s it was demon-
strated that erectile dysfunction was caused
by injury to the branches of the pelvic plexus
that innervate the corpora cavernosa.11 The
so-called nerve-sparing technique allows the
identification and preservation of the bilat-
eral neurovascular bundle, when compatible
with disease control.2
Younger patients tend to fare better in
terms of postoperative potency than their older
counterparts.12
Most patients recover potency after radi-
cal prostatectomy within 6 to 12 months,3 al-
though improvement can continue for up to
2 years postoperatively.
On the other hand, self-injection therapy
with the association of papaverine, phen-
tolamine and prostaglandin E1 is successful
in up to 100% of the general impotent male
population.13
So, our success rate of 94.6% was quite
predictable. In the same way, painful erec-
tions occur in 20.6% of patients during test-
ing and only in 2.9% after this period.14
However, our rate of prolonged erections
(11.3%) is much higher than the published
data of 3.2%,14 probably due to the dosage
used by our patients.
Interestingly, it has been suggested that
early intracavernous therapy, starting one
month after surgery, results in an improved
potency rate after radical prostatectomy.15 This
and the latency time of up to 2 years for po-
tency recovery may easily explain our cure rate
of 13.1% with self-injection therapy.
However, non-controlled bias could have
occurred in the results, as this was an obser-
vational study. The patients’ psychological
profile with respect to their commitment to
treatment could be questioned, as well as
their educational level, leading to better re-
sults in both cases.
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CONCLUSIONS
The modern oral therapy and transure-
thral system for erectile dysfunction used by
67 patients (39.9%) in our series, prior to self-
injection therapy, did not present a satisfac-
tory success rate.
On the other hand, self-injection therapy
using papaverine, phentolamine and prostag-
landin E1 represents a good option for the
treatment of men with erectile dysfunction
after radical prostatectomy. The success rate
is quite high (94.6%) including patients with
a cure rate of about 13%, with very mild side-
effects that resolve spontaneously.
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CONTEXTO: Apesar do recente avanço técnico
na realização da prostatectomia radical
retropúbica, que levou a queda no índice de
complicações, a disfunção erétil ainda é um
problema importante. Além disso, as novas
opções (menos invasivas) de tratamento da
disfunção erétil não mostram resultados
satisfatórios nesse grupo de pacientes.
OBJETIVO: Avaliar a eficácia e efeitos colaterais
da auto-injeção no tratamento da disfunção
erétil causada pela prostatectomia radical,
durante 96 meses.
TIPO DE ESTUDO: Estudo observacional.
LOCAL: Universidade Federal de São Paulo/
Escola Paulista de Medicina.
PARTICIPANTES: 168 pacientes com disfunção
erétil, entre 43 e 78 anos, submetidos a
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RESUMO
prostatectomia radical retropúbica, devido a
câncer localizado da próstata.
PROCEDIMENTOS: Os pacientes foram
tratados com auto-injeção utilizando a
associação de papaverina, fentolamina e
prostaglandina E1 em casa.
RESULTADOS: O índice de sucesso foi de 94,6%
com complicações bastante discretas. Além
disso, tivemos um índice de cura de 13,1%
nesse estudo.
CONCLUSÕES: A auto-injeção com papaverina,
fentolamina e prostaglandina E1 é eficaz e
segura no tratamento da disfunção erétil
causada pela prostatectomia radical.
PALAVRAS-CHAVE: Câncer da próstata.
Disfunção erétil. Auto-injeção intracavernosa.
Prostatectomia radical.
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